

AMC Lab/Translational Scholar Award Program - 2023

The AIDS Malignancy Consortium (AMC) is pleased to announce that it is accepting applications for the AMC Scholar (fellowship) program. The purpose of these awards is to encourage and foster new, junior investigators to pursue careers in AIDS malignancies and to work with the AMC in expanding its translational research portfolio. Applicants must hold a medical degree (such as a Doctor of Medicine (MD), Doctor of Osteopathy (DO), or Bachelor of Medicine Bachelor of Surgery (MB, ChB, MB BS, BM MCh, etc.)), a PhD, or a PhD/DrPH in population science (e.g., epidemiology, biostatistics, health outcomes & behavior). Additionally, applicants must be either completing a mentored fellowship (e.g., clinical fellowship, postdoctoral fellowship) or be junior faculty within 10 years of joining the faculty at an AMC site. Preference will be given to fellows in training or new faculty just beginning a research career in HIV malignancies. Awards will be for one or two years (second year dependent on demonstration of adequate progress and participation in AMC activities in the first year). These awards are designed to allow the individuals to participate in the scientific and clinical activities of the AMC. Scholars should have an interest area within the field of AIDS malignancies research. Scholars should have interest in any laboratory based research area as it relates to HIV malignancies. Applicants must have the endorsement of the local site AMC PI and one or more designated clinical research mentors who will supervise the awardee. A letter from each research mentor outlining the course of study and how it will focus on the study of HIV-related cancers must accompany the application and will be part of the evaluation and selection process. Assurance must be given that the awardee will be provided sufficient protected time to pursue research and to participate in AMC activities. Mentors should also provide assurance that they will meet regularly with and provide guidance to the individual during the award period. Guidance and ongoing interaction with the mentor(s) are critical to the learning process and successful completion of the selected project. Applicants are encouraged to confer with and include a mentor/mentors from outside their institution in additional to a local investigator. The Directors of the AMC Career Enhancement Program are available for consultation and assistance with identifying additional mentor(s). Please contact them via email at AMCscholars@emmes.com if interested.

The applicant must also outline a project to be worked on during the first year of the fellowship. Direct funds up to \$25,000 per year will be awarded to the applicant's institution for the benefit of the awardee's training and participation in AMC activities. Funds may be used towards the scholar's salary or other educational or research needs. Awardees will be required to attend the AMC Group Investigators' meetings which are held twice each year, with travel costs paid by the AMC group for in-person meetings, to present their research projects during the AMC Scholars' Symposium (during in person and virtual meetings), and to participate in career development sessions led by the AMC Scholars Directors. Scholars are also encouraged to participate in protocol team and Working Group discussions, as appropriate. A progress report will be required from the fellow and their mentor(s) prior to the end of the first year of support and at the conclusion of the second year and will be reviewed by the AMC Executive Committee.

Application forms are available and will be accepted once per year. An information session was held on **Tuesday, May 2nd.** The recording for the session will be available via the AMC website at www.AIDSCancer.org > Research > Scholar Award.

Deadline Date for 2023-24 Applications: July 15, 2023

Announcement of Awardees: August 26, 2023

Award will be made for one year with start date of September 1, 2023 to coincide with the AMC fiscal year.

First Year Progress Report Due: June 1, 2024